$20,000.00 in Sales Expected for Biopharmx Corp (BPMX) This Quarter
Equities research analysts predict that Biopharmx Corp (NASDAQ:BPMX) will post $20,000.00 in sales for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Biopharmx Corp’s earnings, with the lowest sales estimate coming in at $10,000.00 and the highest estimate coming in at $30,000.00. Biopharmx Corp posted sales of $30,000.00 during the same quarter last year, which would indicate a negative year-over-year growth rate of 33.3%. The company is scheduled to announce its next quarterly earnings results on Tuesday, December 12th.
On average, analysts expect that Biopharmx Corp will report full year sales of $20,000.00 for the current year, with estimates ranging from $50,000.00 to $570,000.00. For the next financial year, analysts anticipate that the company will report sales of $5.08 million per share, with estimates ranging from $50,000.00 to $15.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that follow Biopharmx Corp.
Biopharmx Corp (NASDAQ:BPMX) last released its quarterly earnings results on Wednesday, September 13th. The company reported ($0.06) EPS for the quarter, meeting analysts’ consensus estimates of ($0.06). The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. Biopharmx Corp had a negative net margin of 22,005.88% and a negative return on equity of 5,749.08%.
BPMX has been the topic of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $3.00 price objective on shares of Biopharmx Corp in a research report on Tuesday, September 19th. Maxim Group reiterated a “buy” rating and issued a $1.50 price target (down from $3.00) on shares of Biopharmx Corp in a report on Wednesday, September 13th.
In related news, major shareholder Franklin Resources Inc purchased 250,000 shares of Biopharmx Corp stock in a transaction on Tuesday, August 1st. The shares were bought at an average cost of $0.34 per share, for a total transaction of $85,000.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
A number of hedge funds and other institutional investors have recently made changes to their positions in BPMX. Vivo Capital LLC increased its holdings in Biopharmx Corp by 10.0% in the 2nd quarter. Vivo Capital LLC now owns 14,096,338 shares of the company’s stock valued at $6,752,000 after acquiring an additional 1,282,052 shares during the last quarter. Vanguard Group Inc. increased its holdings in Biopharmx Corp by 324.6% in the 2nd quarter. Vanguard Group Inc. now owns 1,933,747 shares of the company’s stock valued at $927,000 after acquiring an additional 1,478,338 shares during the last quarter. Finally, Virtu KCG Holdings LLC increased its holdings in Biopharmx Corp by 366.2% in the 2nd quarter. Virtu KCG Holdings LLC now owns 503,418 shares of the company’s stock valued at $241,000 after acquiring an additional 395,424 shares during the last quarter.
ILLEGAL ACTIVITY WARNING: “$20,000.00 in Sales Expected for Biopharmx Corp (BPMX) This Quarter” was published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was illegally stolen and reposted in violation of United States & international copyright and trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/10/24/20000-00-in-sales-expected-for-biopharmx-corp-bpmx-this-quarter-2.html.
Biopharmx Corp (NASDAQ:BPMX) opened at 0.216 on Tuesday. The stock’s market capitalization is $17.21 million. Biopharmx Corp has a 52-week low of $0.19 and a 52-week high of $0.90. The stock’s 50 day moving average is $0.30 and its 200-day moving average is $0.44.
About Biopharmx Corp
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Biopharmx Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx Corp and related companies with MarketBeat.com's FREE daily email newsletter.